Clinical trials: Coagulation
Sepsis, Disseminated Intravascular Coagulation (DIC)
Safflower (Carthamus Tinctorius L.) Granules for Sepsis-associated Coagulopathy
Sepsis is a life-threatening condition in which infection triggers widespread inflammation and blood clotting abnormalities. Many patients with sepsis develop coagulopathy (impaired blood clotting), which contributes to organ…
- Trial name
- HH-SAC (NCT07897006)
- Testing
- High-dose safflower granules, Medium-dose safflower granules
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Pneumonia, Sepsis
Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis
Pneumonia is a lung infection that can cause serious complications, especially when accompanied by sepsis. Sepsis can trigger excessive inflammation and abnormal blood clotting, potentially leading to organ damage and delayed…
- Conditions
- Pneumonia, Sepsis, Blood Coagulation Disorders
- Trial name
- NCT07892794
- Testing
- DLBS1033
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Sebelas Maret
Chronic Primary Immune Thrombocytopenia (ITP)
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
- Trial name
- ITP (NCT07059000)
- Testing
- Kedrion IVIG 10%
- Where
- 28 sites in United States, Czechia and 6 more
- Volunteers
- 40 people
- Sponsor
- Kedrion S.p.A.
Haemophilia A (Moderate or Severe)
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
This is a multinational, prospective, open-label, roll-over study in patients with haemophilia A, ≥6 years of age, who have completed participation in any of the parental studies with efanesoctocog alfa; XTEND-ed study…
- Trial name
- LIBERTY (NCT06716814)
- Testing
- Efanesoctocog alfa
- Where
- 20 sites in Bulgaria, France and 5 more
- Volunteers
- 89 people
- Sponsor
- Swedish Orphan Biovitrum
Sepsis, Venous Thromboembolism
An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related
This is an observational study in which data already collected from people with venous thromboembolism (VTE) due to sepsis (blood poisoning) are studied.
- Conditions
- Sepsis, Venous Thromboembolism, Disseminated Intravascular Coagulation
- Trial name
- NCT06765681
- Testing
- Diagnosis of both VTE and sepsis
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Bayer
Polytrauma, Coagulation Disorder
Comparison of Viscoelastic Measurement by ROTEM® Delta and ClotPro® in Trauma Patients.
The purpose of the study is to describe the differences and interchangeability in measurements of viscoelastic tests of coagulation by two different devices in adult trauma patients.
- Trial name
- ROTCLOT (NCT04107818)
- Where
- Czechia
- Volunteers
- 108 people
- Sponsor
- Masaryk University
Fibrinogen, Spine Deformity
Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery
EFISS is a prospective, randomized, placebo-controlled trial testing the feasibility, safety and efficacy of prophylactic administration of fibrinogen in paediatric spinal surgery.
- Conditions
- Fibrinogen, Spine Deformity, Coagulopathy, Consumption, Bleeding
- Trial name
- EFISS (NCT05391412)
- Testing
- Fibrinogen Concentrate Human
- Where
- Czechia
- Volunteers
- 32 people
- Sponsor
- Brno University Hospital
Sepsis, Coagulopathy
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
Researchers are looking for a better way to treat people who have sepsis induced coagulopathy. Sepsis happens when bacteria and their toxins spread in the blood, causing an infection.
- Trial name
- NCT06854640
- Testing
- BAY3389934
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 36 people
- Sponsor
- Bayer
Severe Hemophilia A
Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
This Phase 1/2 study will be a dose escalation study in adults in 5 cohorts (named cohorts 1, 2, 3, 5 and 6), with the main purpose to assess the safety of subcutaneous injection of OCTA101 (a human-cl rhFVIII and recombinant…
- Trial name
- NCT04046848
- Testing
- OCTA101
- Where
- Bulgaria
- Volunteers
- 36 people
- Sponsor
- Octapharma
Blood Loss, Surgical, Coagulation Disorder
Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
The goal of this clinical trial is to learn if reltodecacog alfa (VMX-C001) works to to allow blood clotting control in participants who take FXa Direct Oral Anticoagulants (DOACs) during surgery or other invasive procedures that…
- Trial name
- EQUILIBRIX-S (NCT07288489)
- Testing
- Reltodecacog alfa, Usual Pharmacological Care
- Where
- 77 sites in United States, Australia and 16 more
- Volunteers
- 800 people
- Sponsor
- VarmX B.V.
Acquired Fibrinogen Deficiency
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS)…
- Trial name
- NCT06617897
- Testing
- CSL511 Fibrinogen concentrate (human), Cryoprecipitate
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- CSL Behring
Hemophilia A
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.
- Trial name
- NCT06940830
- Testing
- Efanesoctocog alfa
- Where
- 31 sites in Croatia, Czechia and 6 more
- Volunteers
- 252 people
- Sponsor
- Swedish Orphan Biovitrum
Coagulation Changes During Coronary Artery Bypass Grafting
Coagulation Profiles in Conventional and Minimal Invasive Extracorporeal Circulation
The aim of this study is to compare the effects of conventional and minimally invasive extracorporeal circulation (MiECC) techniques, which are routinely used in open-heart surgery, on coagulation parameters.
- Trial name
- NCT07844031
- Testing
- Conventional extracorporeal circulation, Minimally invasive extracorporeal circulation
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
Hemophilia A
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan
This is a national, multicenter, retrospective/prospective, observational study in Taiwan designed to assess effectiveness, safety, and usage of efanesoctocog alfa prophylaxis treatment in hemophilia A participants.
- Trial name
- PROTECT-ALT (NCT06684314)
- Testing
- Efanesoctocog alfa
- Where
- 10 sites in Taiwan
- Volunteers
- 79 people
- Sponsor
- Sanofi
Diurnal Variation of Coagulation Function
Exploring the Impact of Diurnal Variation on Coagulation Function in Patients Undering Tumor Surgery
Studies have shown that compared to the evening, the platelet adhension and aggregation functions of normal individuals are stronger in the morning, reaching peak at around 8AM or 9AM.
- Trial name
- NCT07841613
- Testing
- No Biologics
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Pediatric, Coagulation
Reference Range Study for the Quantra System With the QPlus Cartridge in Pediatric Patients
This study will determine reference range intervals for the parameters reported by the Quantra System with the QPlus Cartridge in pediatric patients.
- Trial name
- NCT07447713
- Testing
- Quantra System
- Where
- 4 sites in United States, Switzerland
- Volunteers
- 240 people
- Sponsor
- HemoSonics LLC
Central Venous Catheter, Coagulation
Contact Activation of Coagulation in Newly Inserted Central Venous Catheters
A central venous catheter (CVC) is a thin plastic tube placed into one of the body's large veins, typically in the neck or near the clavicle. CVCs are crucial for administering medications, fluids, and secure blood samples.
- Conditions
- Central Venous Catheter, Coagulation, Coagulation Activation, Central Venous Catheter Complications
- Trial name
- CAS-2 (NCT07014722)
- Testing
- MERITMEDICAL Careflow™ Two-Lumen Central Venous Catheter, ARROW Two-Lumen Central Venous Catheter, ARROWg+ard Blue Plus® Two-Lumen Central Venous Catheter
- Where
- Sweden
- Volunteers
- 88 people
- Sponsor
- Thomas Kander
Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
Post marketing observational study on safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
- Trial name
- NCT06429787
- Testing
- Balfaxar, Kcentra
- Where
- United States
- Volunteers
- 3,574 people
- Sponsor
- Octapharma
Coagulation Disorder, Blood, Prolonged APTT
External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis
Prolonged activated partial thromboplastin time (APTT) is a frequent laboratory finding that may reflect a broad spectrum of underlying conditions, ranging from benign laboratory abnormalities to clinically relevant hemostatic…
- Trial name
- APTTO-EXT (NCT07418099)
- Testing
- Clot waveform analysis-based risk stratification (APTTO models)
- Where
- 16 sites in Spain
- Volunteers
- 1,500 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Coagulation Disorder
Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant
A single centre, double-blind, randomized, placebo-controlled single dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of VMX-C001, conducted in two parts: Part 1: Single dose of…
- Trial name
- NCT06372483
- Testing
- VMX-C001, Rivaroxaban 20 mg Oral Tablet, Apixaban 5 mg Oral Tablet
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.